Biochar is often promoted as a promising tool for climate-smart agriculture, thanks to its ability to store carbon in soils and, in many cases, reduce emissions of nitrous oxide, a powerful greenhouse gas. But a study published in Biochar shows that the climate benefit of biochar is not guaranteed. The way biochar is produced, and the chemical groups present on its surface, can determine whether it helps reduce nitrous oxide or unexpectedly increases it.

A review of 56 field studies reveals that vegetative barriers reduce agricultural runoff by 40% and sediment loss by 63% on average, with even stronger performance in dry climates. Woody barriers outperform grass-only strips, but high variability across sites means effectiveness is hard to predict using simple design rules alone. The researchers offer a probabilistic model to help farmers and land managers make better decisions, positioning vegetative barriers as a practical alternative to cover crops in water-limited regions.

The study unveiled a novel regulation strategy that exhibits exceptional performance in gas sensing applications. This advanced material demonstrates outstanding selectivity, rapid response, and ultrahigh sensitivity, particularly in detecting ammonia (NH₃) molecules. The research, led by a team from East China University of Science and Technology, provides new insights into the gas sensing mechanisms of MXenes and introduces a synergistic strategy to optimize their performance.

The inherent structural instability and insufficient catalytic efficiency of enzymes may affect the reliability and sensitivity of enzyme-based immunosensors, especially in ultra-trace analysis. While covalent organic frameworks (COFs) offer excellent immobilization support due to their structural tunability and stability, conventional physical adsorption risks enzyme leakage, and their dense shells hinder mass transfer. Recent advances in defect engineering allow precise modulation of COF-enzyme interactions, enabling optimized enzyme conformation and activity, providing a promising platform for high-performance biosensors.

Sequential anthracycline and trastuzumab therapy, while highly effective for HER2-positive breast cancer, carries a significant risk of cardiotoxicity, necessitating protective strategies. Qizaobaoxin Decoction (QZBXD), a modified Chinese herbal formula, has demonstrated potential in mitigating such cardiac damage. This investigation systematically delineates the chemical composition of QZBXD and elucidates its cardioprotective efficacy and underlying mechanisms against doxorubicin/trastuzumab (DOX/TRZ)-induced injury. Utilizing UPLC-Q-TOF-MS/MS analysis, 83 compounds were identified, predominantly flavonoids, organic acids, and phthalides. In a rat model of DOX/TRZ-induced cardiotoxicity, QZBXD administration significantly improved cardiac functional parameters, including left ventricular ejection fraction and fractional shortening. It also reduced serum biomarkers of myocardial injury and ameliorated histopathological damage. Mechanistically, multi-omics approaches revealed that QZBXD restored gut microbiota diversity, enriching beneficial bacteria like Bacteroides while suppressing detrimental genera such as Ruminococcus and Oscillibacter. Concurrently, untargeted metabolomics indicated modulation of tryptophan and arachidonic acid metabolic pathways. An integrated analysis established a gut microbiota-metabolite-cardiac axis, demonstrating that QZBXD's cardioprotection is mediated through microbial remodeling and subsequent metabolic reprogramming, providing a pharmacological foundation for its clinical application.

Fanconi anemia (FA), a rare genetic disorder marked by bone marrow failure, congenital anomalies, and cancer predisposition, often presents diagnostic challenges due to phenotypic overlap with other conditions. While FANCAgene mutations account for the majority of FA cases, the complexity of its clinical presentation necessitates comprehensive molecular analysis. This study elucidates the intricate diagnostic pathway for FANCA-related FA within a Chinese family, while simultaneously establishing a critical hereditary differential diagnosis for ectrodactyly (split-hand/foot malformation). Through integrated genomic approaches—including whole-genome sequencing, copy number variation (CNV) analysis, and functional assays—the research uncovers a co-occurrence of pathogenic FANCAmutations and a novel EHMT1splice-site variant. The findings demonstrate that the proband's hematological manifestations stem from biallelic FANCAdefects, whereas the limb anomaly segregates independently with an EHMT1variant, highlighting the necessity of disentangling complex phenotypes for accurate genetic counseling and management.

Diffuse large B-cell lymphoma (DLBCL) presenting with hyperlactatemia or lactic acidosis (LA) represents a rare, often fatal paraneoplastic phenomenon driven by tumor metabolism rather than hypoperfusion. This condition, classified as Type B LA, is frequently misdiagnosed as septic shock due to overlapping clinical features, leading to delayed oncologic intervention. A detailed analysis of two clinical cases combined with a systematic review of 19 published studies reveals critical prognostic thresholds: initial lactate levels between 5–14.9 mmol/L confer a significant survival advantage over levels of 15–24.9 mmol/L, and peak lactate concentration inversely correlates with survival time. Crucially, early initiation of chemotherapy-based regimens, rather than supportive care alone, significantly improves outcomes (P=0.026), establishing LA as an oncologic emergency requiring immediate hematologic workup. Adjunctive therapies, including sodium bicarbonate for severe acidemia and thiamine/Vitamin B supplementation to support mitochondrial function, may provide additional benefit, while medications exacerbating lactate production must be avoided.

Myocardial infarction (MI) and subsequent ischemia-reperfusion injury trigger a devastating cascade of oxidative stress and cardiomyocyte death, largely driven by mitochondrial dysfunction and excessive reactive oxygen species (ROS) production. While the nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant pathway has been extensively studied in cardioprotection, the role of its homolog, Nrf3, remains less clear. Emerging evidence now positions Nrf3 not as a protective factor but as a novel pathogenic driver in post-MI cardiac injury. A pivotal study published in Circulation(Chen et al., 2025) revealed that Nrf3 is significantly upregulated in infarcted human and mouse hearts, where it promotes mitochondrial superoxide generation, exacerbates apoptosis, and impairs cardiac function by epigenetically suppressing the transcription factor Pitx2. This finding challenges the traditional view of the Nrf family as uniformly protective and identifies the Nrf3-Pitx2 axis as a promising therapeutic target for mitigating infarct size and adverse remodeling.